.jpg)
Highlights
- ADQ to acquire Amoun, one of Egypt’s leading pharmaceutical and life sciences companies
- The investment complements ADQ’s strategy to develop a fully integrated value chain in pharmaceuticals
ADQ, one of the region’s largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi’s diversified economy, announced today that it has entered into a definitive agreement to acquire Amoun Pharmaceutical Company S.A.E. (Amoun), one of Egypt’s leading manufacturers, distributors and exporters of branded pharmaceutical and animal health products, from Bausch Health Companies Inc. (Bausch Health).
Amoun has a long-standing reputation for robust pharmaceuticals and life sciences products, addressing a wide range of acute and chronic conditions and highly prevalent diseases that demand treatment with proven high-quality medications. The company’s flagship products include Hibiotic, Antinal, Alphintern, and Neuroton. Amoun has more than 2,500 employees and owns one of the largest, state-of-the-art pharma plants in Egypt.
Fahad Al Qassim added: “Investing in Amoun further solidifies our commitment to the joint investment platform we established with the Sovereign Fund of Egypt (SFE). Together with SFE, we will work with Amoun’s leadership to expand on the company’s proven track record and market position in the pharma landscape.”
The investment in Amoun further strengthens ADQ’s long-term healthcare and pharma strategy to deliver a fully integrated value chain in the UAE. Across ADQ’s healthcare and pharma portfolio, SEHA is leading healthcare provision efforts and the imminent expansion through Pure Health’s diversified services portfolio of hospital management, laboratory services and medical supplies, to extend its reach across the emirates. In addition, ADQ’s recent acquisition of Pharmax locally, along with its investment in Biocon Biologics, will enable access to a wider range of generics and biosimilars, boosting local production capabilities and optimizing pharmaceutical expenditure.
The transaction will be completed through a mandatory tender offer (MTO) by ADQ for the total issued share capital of Amoun, including the less than 1 per cent held by minority shareholders. The transaction is subject to customary closing conditions, including regulatory approvals.
About ADQ
Established in 2018, ADQ is an Abu Dhabi-based investment and holding company with a broad portfolio of major enterprises. Its investments span key sectors of the UAE’s diversified economy including energy and utilities, food and agriculture, healthcare and life sciences, and mobility and logistics, amongst others. As a strategic partner of Abu Dhabi’s government, ADQ is committed to accelerating the transformation of the Emirate into a globally competitive and knowledge-based economy.
For more information, visit adq.ae or write to media@adq.ae. You can also follow ADQ on X, Instagram and LinkedIn.
Direct to your inbox
ADQ News and Insights delivered directly to your inbox
